- Home
- TNGX vs ELVN Comparison
TNGX vs ELVN Comparison
Compare TNGX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | ELVN |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TNGX | ELVN |
|---|---|---|
| Price | $26.50 | $46.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $20.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 2.8M | 1.7M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,384,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $1.04 | $14.79 |
| 52 Week High | $26.81 | $48.53 |
Technical Indicators
Market Signals| Indicator | TNGX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 75.87 | 69.28 |
| Support Level | $6.54 | $17.99 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.46 | 2.51 |
| MACD | 0.44 | 0.29 |
| Stochastic Oscillator | 91.67 | 84.05 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.